Beacon Pointe Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Beacon Pointe Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.3K	Buy	+18,877	New	+$31.1K	﹤0.01%	1818
2025 Q3	–	Sell	-18,845	Closed	-$34.1K	–	1393
2025 Q2	$34.1K	Hold	18,845	–	–	﹤0.01%	1241
2025 Q1	$38.3K	Buy	+18,845	New	+$70.4K	﹤0.01%	1203
2024 Q2	–	Sell	-18,858	Closed	-$851K	–	1285
2024 Q1	$851K	Hold	18,858	–	–	0.01%	743
2023 Q4	$890K	Hold	18,858	–	–	0.01%	705
2023 Q3	$763K	Buy	+18,858	New	+$1.91M	0.01%	714
2023 Q1	–	Sell	-18,884	Closed	-$6.49M	–	1151
2022 Q4	$6.49M	Buy	+18,884	New	+$4.57M	0.13%	162

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Beacon Pointe Advisors's BTAI Position: Q1 2026 in Review

Beacon Pointe Advisors opened a new position in BioXcel Therapeutics (BTAI) in Q1 2026: 18,877 shares worth $25.3K. The stake represents ﹤0.01% of the portfolio and ranks #1818 among its holdings. This is a return to the name: Beacon Pointe Advisors previously reported a position in BTAI as recently as Q2 2025.

Beacon Pointe Advisors first reported a position in BTAI in Q4 2022 and has held it in 7 quarters since. The position peaked at $6.49M in Q4 2022. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

Beacon Pointe Advisors held 18,877 shares of BioXcel Therapeutics worth $25.3K as of Q1 2026.
BioXcel Therapeutics was a new Beacon Pointe Advisors position in Q1 2026.
BioXcel Therapeutics made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q1 2026, its #1818 holding.
Beacon Pointe Advisors first reported a position in BioXcel Therapeutics in Q4 2022 and has held it in 7 quarters since.
Beacon Pointe Advisors's BioXcel Therapeutics position peaked at $6.49M in Q4 2022.
40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.